Johnson & Johnson (NYSE: JNJ) kicked off on Friday, up 1.49% from the previous trading day, before settling in for the closing price of $145.74. Over the past 52 weeks, JNJ has traded in a range of $143.13-$175.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 1.31% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 7.42%. With a float of $2.41 billion, this company’s outstanding shares have now reached $2.41 billion.
In an organization with 131900 employees, it is important to assess its efficiency.
Johnson & Johnson (JNJ) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Johnson & Johnson is 0.16%, while institutional ownership is 71.38%. The most recent insider transaction that took place on Mar 13 ’24, was worth 1,441,765. In this transaction EVP, Global Corp Affairs of this company sold 8,891 shares at a rate of $162.16, taking the stock ownership to the 15,043 shares. Before that another transaction happened on Feb 16 ’24, when Company’s 10% Owner sold 3,725 for $25.81, making the entire transaction worth $96,142. This insider now owns 4,099,575 shares in total.
Johnson & Johnson (JNJ) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 147.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.23% during the next five years compared to -0.27% drop over the previous five years of trading.
Johnson & Johnson (NYSE: JNJ) Trading Performance Indicators
Take a look at Johnson & Johnson’s (JNJ) current performance indicators. Last quarter, stock had a quick ratio of 0.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.98. Likewise, its price to free cash flow for the trailing twelve months is 19.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 7.81, a number that is poised to hit 2.72 in the next quarter and is forecasted to reach 10.99 in one year’s time.
Technical Analysis of Johnson & Johnson (JNJ)
Let’s dig in a bit further. During the last 5-days, its volume was 10.06 million. That was better than the volume of 7.29 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 30.50%. Additionally, its Average True Range was 2.30.
During the past 100 days, Johnson & Johnson’s (JNJ) raw stochastic average was set at 23.37%, which indicates a significant decrease from 32.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 15.96% in the past 14 days, which was higher than the 13.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $156.11, while its 200-day Moving Average is $158.47. However, in the short run, Johnson & Johnson’s stock first resistance to watch stands at $149.18. Second resistance stands at $150.45. The third major resistance level sits at $152.77. If the price goes on to break the first support level at $145.59, it is likely to go to the next support level at $143.27. Assuming the price breaks the second support level, the third support level stands at $142.00.
Johnson & Johnson (NYSE: JNJ) Key Stats
The company with the Market Capitalisation of 356.43 billion has total of 2,409,783K Shares Outstanding. Its annual sales at the moment are 85,159 M in contrast with the sum of 35,153 M annual income. Company’s last quarter sales were recorded 13,532 M and last quarter income was 4,049 M.
